A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas-Reference-Cited by-同舟云学术

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

Published:2014-08 Issue:12 Volume:50 Page:2072-2081
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Infante Jeffrey R.,Somer Bradley G.,Park Joon Oh,Li Chung-Pin,Scheulen Max E.,Kasubhai Saifuddin M.,Oh Do-Youn,Liu Yuan,Redhu Suman,Steplewski Klaudia,Le Ngocdiep

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

3. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group;Moore;J Clin Oncol,2007

4. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer;Bramhall;Br J Cancer,2002

5. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer;Van Cutsem;J Clin Oncol,2004

Cited by 287 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting autophagy can synergize the efficacy of immune checkpoint inhibitors against therapeutic resistance: New promising strategy to reinvigorate cancer therapy;Heliyon;2024-09

2. Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-guided treatment of pancreatic cancer;ESMO Gastrointestinal Oncology;2024-09

3. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer;Science Translational Medicine;2024-08-28

4. Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature;Supportive Care in Cancer;2024-08-23

5. Exploring the Horizon: Anti-Fibroblast Growth Factor Receptor Therapy in Pancreatic Cancer with Aberrant Fibroblast Growth Factor Receptor Expression—A Scoping Review;Cancers;2024-08-22